Download the ESMO 2012 Abstract Book - Oxford Journals

More documents

Recommendations

Info

Annals Of Oncology drug index Oxycodone: 1582P Paclitaxel: 55IN, 80IN, 103IN, 115IN, 154P, 175PD, 191P, 228P, 245O, 246O, 247O, 255PD, 267P, 268P, 269P, 313, 317O, 326PD, 335P, 337P, 345P, 355P, 373P, 382, 405TiP, 454P, 464P, 496P, 505, 681P, 692P, 697P, 698P, 745P, 762, 779TiP, 780TiP, 789O, 790O, 801P, 803P, 804P, 863P, 883, 971PD, 973PD, 974PD, 975PD, 978P, 985P, 986P, 991P, 995P, 997P, 1000P, 1004P, 1010, 1012, 1013, 1017O, 1034P, 1043P, 1153, 1183P, 1204P, 1221, 1224O, 1236PD, 1239P, 1240P, 1242P, 1246P, 1250P, 1255P, 1256P, 1259P, 1276P, 1285P, 1287P, 1297P, 1299P, 1301P, 1303P, 1304P, 1363TiP, 1364TiP, 1524P, 1591P, 1667P Palonosetron: 721P, 1571P, 1572P, 1574P, 1576P, 1577P, 1579P Pamidronic acid: 1585P, 1633 Panitumumab: 29IN, 126IN, 525PD, 535P, 536P, 558P, 563P, 564P, 570P, 572P, 587P, 594P, 598P, 603P, 605P, 631, 634, 652, 665TiP, 667PD, 1016O, 1370P, 1597P Panobinostat: 68IN Pasireotide: 419PD Pazopanib: 29IN, 52IN, 53IN, 54IN, 91IN, 92IN, 222P, 508, 791PD, 792PD, 810P, 816P, 833P, 837P, 840P, 875, 880, 1157O, 1165P, 1493P PDM08: 480P Pegfilgrastim: 1004P, 1547PD, 1548PD, 1553P, 1560P Pegylated liposomal doxorubicin: 984P, 986P, 1594P Pemetrexed: 106IN, 433, 505, 747P, 1022PD, 1206P, 1214, 1215, 1218, 1224O, 1225O, 1235PD, 1242P, 1245P, 1247P, 1251P, 1252P, 1258P, 1267P, 1274P, 1275P, 1281P, 1286P, 1297P, 1302P, 1303P, 1304P, 1326, 1327, 1338, 1342, 1345, 1347, 1354, 1355, 1356, 1361, 1362TiP, 1364TiP, 1370P, 1522PD, 1535P, 1654P Pertuzumab: 202P, 322PD, 344P, 407TiP, 408TiP, 409TiP PF-05212384: 7IN PLX4032: 70IN Pralatrexate: 68IN Prostvac-VF Tricom: 46IN PRRgama: 1703IN PV-10: 1137P R1507: 1497P Racotumomab: 1238PD Radium-223 chloride: 49IN, 898PD, 936P Raltitrexed: 519O, 567P, 747P Ramucirumab: 1115PD, 1245P, 1287P, Ranimustine: 1062O Ranolazine: 1682P Rasburicase: 1103 recPRAME: 1110O, 1182P Regorafenib: 92IN, 173O, 1478O, 1483PD Ridaforolimus (MK-8669): 92IN Rilotumumab: 687P Rituximab: 29IN, 64IN, 65IN, 68IN, 96IN, 97IN, 157P, 1073P, 1076P, 1079P, 1080P, 1373P, 1384P RO4929097: 448PD, 450PD RO4987655: 7IN, 451P RO5126766: 475P Romidepsin: 68IN Rosiglitazone: 590P S-1: 566P, 575P, 576P, 592P, 611P, 646, 668PD, 671PD, 681P, 682P, 688P, 689P, 693P, 698P, 702P, 719P, 728P, 757, 758, 775, 779TiP, 989P, 1181PD, 1234PD, 1334, 1704P Sandostatin-LAR: 1172 SAR-020106: 61IN, 1677P Saracatinib (AZD0530): 501, 1659P SB203580: 348P SB939: 922P Selumetinib: 7IN, 609P, 1233PD Silumarin: 473P Sipuleucel-T: 46IN, 53IN, 939P, 940P, 941P, 942P, 943P, 949, 950 SLO101: 1674P SN38: 485P, 664TiP Somatostatin: 75IN, 419PD, 873, 1167P, 1172 Sorafenib: 7IN, 29IN, 43IN, 53IN, 124IN, 173O, 229P, 447PD, 466P, 569P, 654, 670PD, 734P, 736P, 737P, 744P, 770, 777TiP, 778TiP, 781TiP, 793PD, 795PD, 810P, 812P, 816P, 817P, 818P, 823P, 824P, 837P, 840P, 843P, 844P, 846P, 848P, 856P, 869, 871, 872, 874, 875, 877, 879, 881, 1165P, 1241P, 1349, 1362TiP, 1370P, 1390P, 1391P, 1401P, 1491P, 1506P, 1594P, 1615P, 1674P Streptozocin: 209P, 1159P, 1161P Sunitinib: 29IN, 52IN, 53IN, 58IN, 76IN, 92IN, 95IN, 174O, 229P, 508, 705P, 724P, 785O, 792PD, 793PD, 794PD, 797PD, 81OP, 812P, 815P, 816P, 818P, 820P, 821P, 823P, 824P, 826P, 827P, 829P, 830P, 832P, 834P, 835P, 837P, 840P, 843P, 846P, 847P, 848P,849P, 850P, 851P, 853P, 854P, 856P, 869, 870, 872, 875, 877, 879, 881, 889TiP, 892TIP, 901PD, 1155O, 1163P, 1165P, 1370P, 1401P, 1478O, 1483PD, 1484PD, 1490P, 1491P, 1495P, 1496P, 1550PD, 1615P, 1678P, 1703IN TAK-441: 449PD TAK-700: 918P TAK-733: 456P, Talactoferrin: 1363TiP, Tamoxifen: 14IN, 17IN, 196P, 249PD, 279P, 280P, 295P, 311, 339P, 360P, 384, 1147, 1502P TAS-102: 126IN Tasquinimod: 919P T-DM1: 318O Temozolomide: 410O, 416PD, 424P, 426P, 436TiP, 437TiP, 1126P, 1135P, 1368TiP, 1529P, 1676P, 1686P, 1703IN Temsirolimus: 65IN, 68IN, 420PD, 450PD, 462P, 717P, 793PD, 810P, 816P, 818P, 824P, 828P, 839P, 845P, 846P, 852P, 875, 879, 1023PD, 1107TiP Tesetaxel: 481P, 486P TH-302: 435TiP, 666O Thalidomide: 1088P Thiotepa: 789O Tigatuzumab (CS-1008): 662TiP Tipifarnib: 43IN Tivatinib: 738P, 739P, 1293P Tivozanib: 53IN, 795PD, 796PD, 892TiP TNFalpha: 1504P Tocilizumab: 153P Topotecan: 968O, 986P, 1529P Trabectedin: 984P, 986P, 1511P, 1517TiP Trastuzumab: 6IN, 7IN, 29IN, 44IN, 53IN, 57IN, 103IN, 104IN, 115IN, 154P, 202P, 226P, 228P, 243, 246O, 247O, 245PD, 255PD, 266P, 267P, 268P, 270P, 271P, 272P, 273P, 274P, 275P, 276P, 308, 309, 315TiP, 318O, 322PD, 325PD, 337P, 343P, 344P, 346P, 373P, 380, 389, 391, 393, 396, 404, 406TiP, 407TiP, 408TiP, 40TiP, 454P, 470P, 476P, 496P, 677P, 699P, 761, 762, 786O, 1232PD, 1373P, 1397P, 1398P, 1646PD, 1657P TSU-68: 732P U3-1287: 467P Uracil-tegafur (UFT): 542P, 552P, 575P, 576P, 582P, 611P, 623, 625, 628, 681P Vandetanib: 7IN, 508, 804P Vedotin: 68IN, 1083P Veliparib: 428P Vemurafenib: 6IN, 28IN, 29IN, 227P, 242, 1124P, 1125P, 1146 Vinblastine: 799P, 802P, 807P, 860P, 1138P Vincristine: 1062O, 1063O, 1071P, 1073P, 1074P, 1079P, 1080P, 1098, 1525P, 1529P Vindesine: 1062O, 1204P, 1234PD Vinflunine: 21IN, 787O, 804P Vinorelbine: 80IN, 106IN, 168O, 391, 392, 393, 394, 399, 408TiP, 1058, 1183P, 1199P, 1201P, 1202P, 1243P, 1247P, 1249P, 1272P, 1276P, 1286P, 1297P, 1301P, 1304P, 1329, 1337, 1356, 1357, 1502P, 1542TiP, 1645PD Vismodegib: 1111PD, 1112PD Volasertib: 804P Vorinostat: 68IN, 700P, 1273P, XL-147: 7IN XL-765: 7IN XL880: 1027P Y-27632: 947 Y90 Iritumomab: 1073P, Y-DOTATOC: 75IN, 1703IN YS110: 498P YTTRIUM-90: 735P Zalypsis: 806P Zoledronic acid: 49IN, 937P, 945, 1108TiP, 1321, 1580P, 1583P, 1584P, 1585P, 1633, 1641 Volume 23 | Supplement 9 | September 2012 doi:10.1093/annonc/mds479 | ix603 drug index
translational research index translational research index 3’-UTR: 1032P 4EB-P1: 5HT3: 129IN 9F1: 562P A488G: 374P ABCA13: 1701 ABCB1: 724P, 1667P, 1678P ABCG2: 215P, 64O, 724P ABL1: 1311P ACC: 618 ACTN4: 1174P, 1186P, 1701 Adiponectin: 190P AEG-1: 807P AFP: T33P, 790O, 866P, 994P, 1539P, 1693P AFR: 1211 AKR1C: 928P, 1701 AKT: 2IN, 7IN,52IN, 65IN, 76IN, 90IN, 102IN, 107IN, 108IN, 119IN, 154P, 156P, 173O, 179P, 180P, 185P, 214P, 318O, 343P, 347P, 350P, 41PD, 442O, 450PD, 458P, 474P, 483P, 781TiP, 807P, 812P, 80TiP, 917P, 1031P, 1196P, 1491P, 1652P, 1659P, 1668P, 1675P, 1676P, 1685P, 1690P ALCAM: 215P, 720P ALDH1: 149P, 216P, 375P ALDH2: 1701 ALK: 6IN, 7IN, 62IN, 78IN, 81IN, 82IN, 83IN, 108IN, 119IN, 138IN, 167O, 193P, 195P, 438O, 439O, 440O, 441O, 1063O, 1176P, 1187P, 1191PD, 1193P, 1195P, 1208, 1230PD, 1231PD, 1248P, 1266P, 1267P, 1268P, 1274P, 1284P, 1290P, 1312, 1324, 1497P, 1647PD, 1664P ALPHA-2A: 299 ALPHA-6: 214P Amphiregulin: 526PD, 536P AMPK: 618 Ang-1: 975PD Ang-2: 184P, 600P, 794PD, 975PD, 1648P Annexin A4: ANP: 1682P ANXA: 1701 APC: 7IN, 92IN, 675P APOA1: 232 Apoptosis: 66IN, 81IN, 109IN, 148P, 149P, 156P, 158P, 165, 173O, 177PD, 179P, 236, 482P, 539P, 575P, 769, 806P, 988P, 1122P, 1677P, 1682P AR: 20IN, 48IN, 257P, 325PD, 899PD, 900PD, 922P, 924P, 925P, 1680P, 1689P ASL: 1660P ASS1: 1660P ATM: 7IN, 156P, 186P ATP: 159P, 166, 444PD, 458P, 495P ATRX: 12IN AURKA: 93IN Aurora-A kinase: 376, 461P, 489P, 921P AXL: 1027P B-actin: 1170P Bad: 156P, 405TiP BALP: 805P, 945, 1122P BAP1: 1300P Bax: 628, 1122P Bcl-2: 65IN, 156P, 249PD, 482P, 1075P Bcl-xl: 769, 1075P BCR-ABL: 1093P, 1481PD, 1102, 1105 BDNF: 188P, 1464P Beclin-1: 1679P BETA: 179P, 214P, 299 Beta-catenin: 675P, 703P, 1700 beta-CTX: 805P, 945 bFGF: 152P, 842P, 1236PD, 1657P BHCG: 790O, 865P, 994P BHR: 66IN BIM: 154P, 185P BIP/GRP78: 66IN Bmi1: 144PD BMP4: 720P BNIP3: 1033P BNP: 1682P BRAF: 6IN, 7IN, 19IN, 28IN, 29IN, 50IN, 70IN, 78IN, 83IN, 102IN, 108IN, 119IN, 180P, 208P, 212P, 227P, 237, 456P, 475P, 521O, 525PD, 526PD, 532P, 535P, 536P, 537P, 548P, 557P, 574P, 580P, 593P, 608P, 629, 631, 641, 656, 696P, 1017O, 1118PD, 1123P, 1124P, 1125P, 1135P, 1145, 1146, 1147, 1173, 1187P, 1349, 1491P, 1647PD, 1649P, 1652P, 1664P BRCA: 55IN, 220P BRCA1: 7IN, 17IN, 20IN,33IN, 35IN, 36IN, 187P, 294P, 511PD, 512PD, 513PD, 514P, 515P, 686P, 720P, 807P, 969PD, 972PD, 1170P, 1300P, 1449P, 1542TiP, 1655P, 1661P, 1662P BRCA2: 33IN, 35IN, 36IN, 294P, 371P, 511PD, 512PD, 513PD, 514P, 515P, 720P, 969PD, 972PD, 1449P, 1662P BRM: 186P BTK: 65IN, 68IN BXPC3: 1697P C26: 477P C3: 232 C4: 232 CA 72-4: 679P CA: 786O, 1167P CA125: 147P, 972PD, 978P, 983P, 987P, 1012, 1013, 1203P CA15-3: 302, 339P, 376, 388 CA19-9: 645, 666O, 679P, 713P, 721P CA9: 1033P CACO-2: 229P CADM1: 221P CAF: 833P CA-IX: 185P, 435TiP, 562P, 794PD, 835P, 1695P CALR: 1701 Calreticulin: 495P Calretinin: 1533P Cancer stem cells: 375P, 385, 418PD, 463P Caspase-3: 443PD CBFB: 102IN CCL2: 838P CCNA2: 215P CCNB1: 24PD CCND: 180P, 1031P CCNE: 180P CD10: 287P, 1106 CD105: 169O CD117: 1067PD, 1106 CD11b: 480P, 1314 CD127: 1138P, 1314 CD13: 1314 CD133: 149P, 159P, 418PD, 431, 604P CD135: 1067PD CD138: 66IN CD14: 1314 CD144: 227P CD15: 480P, 676P, 1314 CD154: 813P CD163: 1681P CD16b: 480P CD19: 1106 CD2: 1106 CD20: 64IN, 157P, 216P, 1079P CD22: 1106 CD24: 720P CD25: 1138P, 1314 CD26: 498P Published by Oxford University Press on behalf of the European Society for Medical Oncology. Annals Of Oncology 23 (Supplement 9): ix604–ix608, 2012 doi:10.1093/annonc/mds480 CD3: 495P, 939P, 1106, 1314, 1644PD CD30: 861P, 1063O, 1083P CD31: 443PD, 501 CD33: 480P, 1106, 1314 CD34: 751, 1083P, 1085P, 1489P, 1106, 1624 CD39: 1314 CD4: 436TiP, 480P, 495P, 622, 915P, 939P, 1106, 1110O, 1117PD, 1138P, 1314, CD40: 1645P CD44: 720P, 1685P CD44+/CD24-: 149P, 164, 215P, 300, 375P, 1696P CD45: 227P, 480P, 1067PD, 1175P, 1512, 1650P CD45RO: 622, 1314 CD46: 1677P CD49f: 1685P CD5: 1106 CD54: 942P CD56: 480P, 1543TiP, 1644PD CD68: 1681P CD7: 1106 CD74: 195P CD8: 436TiP, 495P, 503, 915P, 939P, 1110O, 1114PD, 1117PD, 1314 CD80: 510TiP, 813P CD83: 510TiP, 1672P CD86: 510TiP, 1673P CDH1: 225P, 511PD CDH13: 221P, 548P CDK4: 70IN, 92IN, 93IN CDKN2A: 7IN, 12IN, 180P, 720P, 1118PD CDS: 1032P CDX2: 675P CEA: 339P, 388, 505, 518O, 579P, 583P, 622, 627, 637, 644, 645, 647, 653, 659, 679P, 911P, 1203P, 1313 CEBPA: 93IN CFDNA: 219P CHFR: 221P CHK1: 20IN, 61IN, 1677P CHR: 615 Chromogranin A: 911P, 912P Circulating endothelial cells: 209P, 567P, 1240P Circulating endothelial progenitors: 1240P Circulating tumor cells (CTCs): 171O, 217P, 218P, 223P, 227P, 230P, 255PD, 304, 582P, 767, 897O, 900PD, 910P, 911P, 922P, 961, 963TiP, 965TiP, 1029P, 1175P, 1240P, 1313, 1512, 1650P CIT: 229P CKB: 1701 Class III beta tubulin: 187P, 291P Clec14: 178P CMCS: 21P, 227P c-MET: 7IN, 51IN, 70IN, 78IN, 83IN, 102IN, 119IN, 143PD, 179P, 205P, 443PD, 444PD, 445PD, 471P, 492P, 493P, 669PD, 687P, 720P, 738P, 739P, 897O, 1027P, 1191PD, 1198P, 1290P, 1291P, 1219P, 1293P, 1309P, 1322, 1365TiP, 1532P COL1A1: 215P COX-2: 538P, 720P, 1026P, 1502P, 1652P Cparp: 154P C-RAF: 1349 CSF1R: 102IN CTC: 223P CTDNEP1: 25IN CTGF: 1682P CTLA4: 22IN, 46IN, 53IN, 71IN, 175PD, 915P, 1149 CTNNB1: 7IN, 12IN, 25IN CXCL1: 228P CXCL10: 865P CXCL12: 1688PD
Page 1 and 2:
Annals of Oncology www.annonc.oxfor
Page 3 and 4:
subscriptions A subscription to Ann
Page 6 and 7:
Annals of Oncology Official Journal
Page 8 and 9:
The European Society for Medical On
Page 10 and 11:
Audit Committee Chair: Fortunato Ci
Page 12 and 13:
Familial cancer Judith Balmaña, Ba
Page 14 and 15:
ESMO 2012 Congress Travel Grants 47
Page 16 and 17:
Exhibitors The following companies
Page 18 and 19:
ESMO Fellowships, 1989-2011 The Eur
Page 20:
Ondrej Gojis, Czech Republic 2008-2
Page 23 and 24:
abstracts hpv biology and implicati
Page 25 and 26:
abstracts the characterization of l
Page 27 and 28:
abstracts description of intra-tumo
Page 29 and 30:
prevent cell death. It is anticipat
Page 31 and 32:
22IN TARGETING THE HOST IN TNBC G.
Page 33 and 34:
abstracts a paradigm shift in early
Page 35 and 36:
abstracts how can medical oncologis
Page 37 and 38:
feasibility), but by how high the c
Page 39 and 40:
abstracts re-inventing the medical
Page 41 and 42:
abstracts emerging diagnostic and t
Page 43 and 44:
abstracts biologically based treatm
Page 45 and 46:
abstracts molecular targets in mali
Page 47 and 48:
abstracts melanoma therapy: from fr
Page 49 and 50:
diagnosis and can also be used for
Page 51 and 52:
analysis at 11 months median follow
Page 53 and 54:
mouse model of Kras mutant NSCLC. I
Page 55 and 56:
abstracts subtyping soft tissue sar
Page 57 and 58:
abstracts key topics in supportive
Page 59 and 60:
ESMO-CSCO Joint Symposium: Building
Page 61 and 62:
ESMO-EANM-ESR Joint Symposium: Imag
Page 63 and 64:
ESMO-ESTRO Joint Symposium: Innovat
Page 65 and 66:
ESMO-MASCC Joint Symposium: Integra
Page 67 and 68:
ESO Society Symposium: Celebrating
Page 69 and 70:
Results: TIMP-1 expression was incr
Page 71 and 72:
will benefit from this targeted the
Page 73 and 74:
cytomegalovirus (CMV). Analysis of
Page 75 and 76:
functional consequences of Endoglin
Page 77 and 78:
elationship between the ROR score,
Page 79 and 80:
183P EPIDERMAL GROWTH FACTOR RECEPT
Page 81 and 82:
Plasma adiponectin level on the pre
Page 83 and 84:
Table: 198P PFS OS Median, mo HR Me
Page 85 and 86:
204P EVALUATION OF PTEN AND PIK3CA
Page 87 and 88:
Material and methods: We searched P
Page 89 and 90:
Results: The median concentration o
Page 91 and 92:
Table: 226P Methods: Pts were rando
Page 93 and 94:
However, additional analysis sugges
Page 95 and 96:
number of biomarkers have been trie
Page 97 and 98:
Table: 248O 249PD PROTEOMIC PREDICT
Page 99 and 100:
Conclusions: BW and serum Ctrough o
Page 101 and 102:
261P BREAST CANCER SUBTYPES AND OUT
Page 103 and 104:
90 mg/m2-cyclophophamide 600 mg/m2
Page 105 and 106:
to 9 weeks after dosing. Trastuzuma
Page 107 and 108:
Patients and methods: We reviewed d
Page 109 and 110:
sector patients. The aim of this st
Page 111 and 112:
Linear Logistic Model with Relaxed
Page 113 and 114:
Results: The median CTC fold change
Page 115 and 116:
312: Table: Chemotherapy uptake wit
Page 117 and 118:
abstracts breast cancer, locally ad
Page 119 and 120:
Results: 8 trials (2092 pts) with 1
Page 121 and 122:
absolute difference of median value
Page 123 and 124:
Novartis, Genentech, and sanofi-ave
Page 125 and 126:
Results: Three RCTs with 1023 patie
Page 127 and 128:
collected from all patients for det
Page 129 and 130:
355P FIRST REPORT OF LONG-TERM RESP
Page 131 and 132:
361P A RETROSPECTIVE ANALYSIS OF PL
Page 133 and 134:
publications and aggregated in a me
Page 135 and 136:
Thus the primary aim to target BCSC
Page 137 and 138:
383 WHY DO WOMEN WITH BREAST CANCER
Page 139 and 140:
Results: We evaluated 76 pts with M
Page 141 and 142:
more than 6 cycles of capecitabine.
Page 143 and 144:
406TiP PHASE II TRIAL OF PRIMARY SY
Page 145 and 146:
abstracts CNS tumors 410O CONDITION
Page 147 and 148:
Conclusions: Our data suggested tha
Page 149 and 150:
Conclusions: As in other cancer typ
Page 151 and 152:
432 GAMMA KNIFE RADIOSURGERY AS A M
Page 153 and 154:
abstracts developmental therapeutic
Page 155 and 156:
1PR), but no responses were seen in
Page 157 and 158:
RO and Cd, as well as PD data for c
Page 159 and 160:
and vulvar Ca), and 11 SDs were obs
Page 161 and 162:
knowing HLA-A status double-blindly
Page 163 and 164:
Acquired-resistance to EGFR inhibit
Page 165 and 166:
474P PHASE 1 STUDY OF THE SELECTIVE
Page 167 and 168:
TST is active in breast and gastric
Page 169 and 170:
Treatment-induced shedding of circu
Page 171 and 172:
Methods: Either co-cultures of peri
Page 173 and 174:
501 PRECLINICAL DATA INVESTIGATING
Page 175 and 176:
509TiP LUX-LUNG 8: A RANDOMIZED, OP
Page 177 and 178:
(P = 0.64). Synchronous BBC was sig
Page 179 and 180:
abstracts gastrointestinal tumors,
Page 181 and 182:
Disclosure: M. Lee: I am an employe
Page 183 and 184:
plus intravenous Bev(7.5mg/kg q 21d
Page 185 and 186:
anti-EGFR treatment. The present st
Page 187 and 188:
patients harboring a T/T genotype t
Page 189 and 190:
551P ADJUVANT CHEMOTHERAPY (AC) USE
Page 191 and 192:
experienced significantly more ≥
Page 193 and 194:
functioning scales. Exploratory ana
Page 195 and 196:
oxaliplatin (100 mg/m 2 )/raltitrex
Page 197 and 198:
572P PANERB STUDY: WHICH CATEGORY O
Page 199 and 200:
Results: 92/114 patients were preop
Page 201 and 202:
585P CHANGES IN THE INTESTINAL ENVI
Page 203 and 204:
592P PHASE II TRIAL OF COMBINED CHE
Page 205 and 206:
minutes. In a previous study, 30-mi
Page 207 and 208:
Patients and methods: Chemotherapy-
Page 209 and 210:
612P ARE PATIENTS WITH RESECTABLE R
Page 211 and 212:
Conclusions: AMPK and ACC activatio
Page 213 and 214:
of surgical monotherapy in patients
Page 215 and 216:
Table: 632 633 AFLIBERCEPT/FOLFIRI
Page 217 and 218:
factors play the determining role i
Page 219 and 220:
Abstract withdrawn in exceptional c
Page 221 and 222:
were respectively 10.6 vs 8.5 vs 3.
Page 223 and 224:
Results: 20 gastrointestinal cancer
Page 225 and 226:
abstracts gastrointestinal tumors,
Page 227 and 228:
Day 8. A second identical course wa
Page 229 and 230:
proven in stage I GC. The aim of th
Page 231 and 232:
Conclusions: Longer OS to FOLFOX wa
Page 233 and 234:
692P PRELIMINARY SAFETY DATA FROM A
Page 235 and 236:
subgroup. Taking into consideration
Page 237 and 238:
Results: Three years of adjuvant im
Page 239 and 240:
considered sufficient to give an 80
Page 241 and 242:
721P FIRST-LINE TREATMENT WITH FOLF
Page 243 and 244:
after Gem-based therapy. The additi
Page 245 and 246:
735P RADIOGRAPHIC PARAMETERS IN PRE
Page 247 and 248:
validate the revised AJCC 7th stagi
Page 249 and 250:
Results: Among 862 MM we identified
Page 251 and 252:
Results: Frequently reported advers
Page 253 and 254:
gastric cancer patients with CNS me
Page 255 and 256:
discriminate the prognosis of HCC p
Page 257 and 258:
prospective, non-interventional stu
Page 259 and 260:
abstracts genitourinary tumors, non
Page 261 and 262:
787O EXTERNAL VALIDATION OF THE ASS
Page 263 and 264:
patient preference for P over S, an
Page 265 and 266:
798PD OPEN-LABEL PHASE II TRIAL OF
Page 267 and 268:
Hb, PS and LM. Median PFS for patie
Page 269 and 270:
may have led to reduced dose and sh
Page 271 and 272:
Results: 1,622 patients were identi
Page 273 and 274:
RCC) was designed to address an unm
Page 275 and 276:
Patients and methods: This is a sin
Page 277 and 278:
treatment at week 4, and week 12 by
Page 279 and 280:
effective in second or further line
Page 281 and 282:
Conclusions: In pts with RCC treate
Page 283 and 284:
using Drug inCode ® pharmacogeneti
Page 285 and 286:
Table: 857P standard, but is not av
Page 287 and 288:
efused HDCT. Of 23 patients, 20 com
Page 289 and 290:
we identified 49 and 220 patients w
Page 291 and 292:
879 TREATMENT OF PATIENTS WITH META
Page 293 and 294:
Median overall survival (OS) was 26
Page 295 and 296:
abstracts Genitourinary tumors, pro
Page 297 and 298:
and week 13 BPI-SF Q3 scores), 28%
Page 299 and 300:
Working Group (PCWG)-2 guidelines r
Page 301 and 302:
atio HR 0.39; CI 0.18, 0.83, p = 0.
Page 303 and 304:
We observed tumor responses and pro
Page 305 and 306:
Here we report emerging data from t
Page 307 and 308:
928P LHRH AGONIST-INDUCED SUPPRESSI
Page 309 and 310:
Disclosure: S. Oudard: Has acted as
Page 311 and 312:
939P NEOADJUVANT SIPULEUCEL-T IN LO
Page 313 and 314:
945 BONE TURNOVER MARKERS AND POTEN
Page 315 and 316:
952 SEQUENTIAL ANDROGEN DEPRIVATION
Page 317 and 318:
managed in a multidisciplinary (MD)
Page 319 and 320:
or hypercalcemia at screening; prio
Page 321 and 322:
meeting. The prevalence of LGSC is
Page 323 and 324:
Table: 975PD Continued AMG 386 + pa
Page 325 and 326:
physicians in the U.S. and Europe.
Page 327 and 328:
989P PHASE II STUDY OF COMBINATION
Page 329 and 330:
elated with stage, nodal involvemen
Page 331 and 332:
1004P CASE CONTROL STUDY ON TWO DIF
Page 333 and 334:
eight patients who had infertility
Page 335 and 336:
abstracts head and neck cancer 1016
Page 337 and 338:
same CT/RT; Arm B2: 3 cycles of ind
Page 339 and 340:
induction chemotherapy in the treat
Page 341 and 342:
patients. We have developed a rando
Page 343 and 344:
evaluated by the screening instrume
Page 345 and 346:
morbidities that radiation would le
Page 347 and 348:
Conclusions: Through adequate selec
Page 349 and 350:
abstracts hematological malignancie
Page 351 and 352:
anthracyclines in vitro. A favorabl
Page 353 and 354:
1076P RITUXIMAB PLUS SUBCUTANEOUS C
Page 355 and 356:
than the standard target of ≥2.5
Page 357 and 358:
Patients: From November 2002 to May
Page 359 and 360:
lymphadenopathy and multiple cutane
Page 361 and 362:
prospective non-interventional stud
Page 363 and 364:
Funding: GSK Biologicals Disclosure
Page 365 and 366:
survival rates of 13-25% (Prieto et
Page 367 and 368:
high response rates and prolonged p
Page 369 and 370:
GlaxoSmithKline, Merck Sharp & Dohm
Page 371 and 372:
advisor for Merck Sharp & Dohme, an
Page 373 and 374:
or cutaneous melanoma. A survival u
Page 375 and 376:
systemic therapy or were intolerant
Page 377 and 378:
abstracts neuroendocrine tumors and
Page 379 and 380:
morbidity, with G3 tumors behaving
Page 381 and 382:
pts. Poorly differentiated endocrin
Page 383 and 384:
Adenocarcinoma was present in 25 pa
Page 385 and 386:
Method: Endobronchial ultrasound gu
Page 387 and 388:
widely used by single agent or plat
Page 389 and 390:
disease after surgery were treated
Page 391 and 392:
stage IIIA NSCLC, EML4-ALK fusion-p
Page 393 and 394:
1200P CONCOMITANT CHEMORADIATION GI
Page 395 and 396:
Patients and methods: The study was
Page 397 and 398:
months (95% CI:13-25). The PFS and
Page 399 and 400:
maintenance therapy had favourable
Page 401 and 402:
abstracts non-small cell lung cance
Page 403 and 404:
Ingelheim, GSK Biologicals (compens
Page 405 and 406:
1234PD RANDOMIZED PHASE III TRIAL O
Page 407 and 408:
GlaxoSmithKline (myself, compensate
Page 409 and 410:
1243P IDENTIFICATION OF MICRORNA (M
Page 411 and 412:
N-arm n=34 P-arm n=32 All n=66 Male
Page 413 and 414:
1255P POPULATION BASED EVALUATION O
Page 415 and 416:
1262P DISTINCT SPREAD OF EGFR MUTAT
Page 417 and 418:
1268P VISUAL DISTURBANCES IN PATIEN
Page 419 and 420:
MERCK SERONO: Advisor, speaker in s
Page 421 and 422:
Conclusions: These data from SAiL a
Page 423 and 424:
NSCLC diagnosis and time of BM diag
Page 425 and 426:
1291P PHASE I/II DOSE-FINDING STUDY
Page 427 and 428:
Network utilization of WBCGF in the
Page 429 and 430:
1303P COST EFFECTIVENESS OF PEMETRE
Page 431 and 432:
Results: The patients’ characteri
Page 433 and 434:
EGFR mut at exons 18, 19, 21, and K
Page 435 and 436:
Methods: EML4-ALK fusion was screen
Page 437 and 438:
Results: The median survival time (
Page 439 and 440:
enefit from sustained EGFR blockade
Page 441 and 442:
epresented by 19 pts (32%) female,
Page 443 and 444:
and at least one prior course of ch
Page 445 and 446:
Methods: NSCLC patients with radiog
Page 447 and 448:
1367TiP LONG-TERM ERLOTINIB THERAPY
Page 449 and 450:
Austria, Czech Republic, Finland, G
Page 451 and 452:
were every 6 weeks (wk) (S1), every
Page 453 and 454:
Advantage enrollees (83% vs. 25%) [
Page 455 and 456:
Results: Based on 10,000 simulation
Page 457 and 458:
cancer tumors 12%, Germ cell tumor
Page 459 and 460:
Material and methods: 50 lung cance
Page 461 and 462:
1414TiP IMPLEMENTATION OF CANCER RE
Page 463 and 464:
abstracts palliative care 1422O EFF
Page 465 and 466:
Method and results: A total of 317
Page 467 and 468:
1436P SURVEY ON MODELS OF INTEGRATI
Page 469 and 470:
care unit (PCU) at the National Can
Page 471 and 472:
Characteristic No. % Total 63 1 st
Page 473 and 474:
hysterectomised-9.10% and cervix ca
Page 475 and 476:
abstracts psycho-oncology 1462PD IN
Page 477 and 478:
events, tumour response, and surviv
Page 479 and 480:
abstracts sarcoma 1477O ADHESION TO
Page 481 and 482:
1481PD A PHASE II STUDY OF DOVITINI
Page 483 and 484:
1488P ORGANISATION OF SARCOMA PATIE
Page 485 and 486:
Patients and methods: From August 2
Page 487 and 488:
chemotherapy respectively. At a med
Page 489 and 490:
of this group Those with relapsed d
Page 491 and 492:
1515 PREDICTORS OF SURVIVAL IN ADOL
Page 493 and 494:
abstracts small cell lung cancer an
Page 495 and 496:
emaining receiving either CAV or to
Page 497 and 498:
1533P EXPRESSION OF WILM⍰TUMOUR G
Page 499 and 500:
more than 3 months after first line
Page 501 and 502:
lower recurrence rate of NE. Pegfil
Page 503 and 504:
egimens (HR = 2.5, p < 0.001). Phys
Page 505 and 506:
1561P PREDICTIVE DIAGNOSTICS FOR RE
Page 507 and 508:
Methods: A prospective multicentre
Page 509 and 510:
Table: 1574P Pharmacokinetic parame
Page 511 and 512:
Novartis and unrestricted research
Page 513 and 514:
studies have shown that chemotherap
Page 515 and 516:
(Grade 1) and moderate to severe (G
Page 517 and 518:
declined to relatively lower level
Page 519 and 520:
1609P PHYSICAL ACTIVITY (PA) AND PH
Page 521 and 522:
patients were admitted to the oncol
Page 523 and 524:
Dicarbamin 100 mg/day on day 5 befo
Page 525 and 526:
Results: Anemia was detected in 83.
Page 527 and 528:
important to carry out randomized s
Page 529 and 530:
abstracts translational research 16
Page 531 and 532:
expression. Then, we analyzed PB sa
Page 533 and 534:
Table: 1657P TH BV + TH HR (95% CI)
Page 535 and 536:
BRAF mutations. Circulating free DN
Page 537 and 538:
1671P PHASE I CLINICAL TRIAL OF CAN
Page 539 and 540:
1678P PREDICTIVE VALUE OF TWO PHENO
Page 541 and 542:
theorized that the PI3K/AKT pathway
Page 543 and 544:
Material and methods: 101 patients
Page 545 and 546:
overexpressing and 232 had triple n
Page 547 and 548:
author index author index A Aamdal
Page 549 and 550:
author index Badran A. ix288 (874)
Page 551 and 552:
author index Bösmüller H. ix209 (
Page 553 and 554: author index Chen A. ix319 (966O) C
Page 555 and 556: author index De Droogh E. ix452 (13
Page 557 and 558: author index Esposito G. ix209 (618
Page 559 and 560: author index Geiges G. ix306 (930P)
Page 561 and 562: author index Hartono S. ix70 (155P)
Page 563 and 564: author index Iwasaki H. ix542 (1694
Page 565 and 566: author index Kodaira M. ix90 (228P)
Page 567 and 568: author index Lichtensztejn D. ix350
Page 569 and 570: author index Martinez A. ix496 (153
Page 571 and 572: author index Morishita N. ix432 (13
Page 573 and 574: author index Okamoto N. ix432 (1320
Page 575 and 576: author index Piau S. ix456 (1401P)
Page 577 and 578: author index Rodríguez Rodríguez
Page 579 and 580: author index Scoggins C.R. ix371 (1
Page 581 and 582: author index Stern L. ix272 (823P)
Page 583 and 584: author index Trypaki M. ix429 (1308
Page 585 and 586: author index Whitmore J.B. ix310 (9
Page 587 and 588: subject index subject index A AAV-H
Page 589 and 590: subject index ix115 (316TiP), ix116
Page 591 and 592: subject index diffuse large B-cell
Page 593 and 594: subject index (1033P), ix340 (1036P
Page 595 and 596: subject index medical information,
Page 597 and 598: subject index (612P), ix214 (633),
Page 599 and 600: subject index RCC, ix274 (830P) re-
Page 601 and 602: subject index TR-FRET, ix84 (206P)
Page 603: drug index drug index 1248P, 1250P,
Page 607 and 608: translational research index transl
Page 609: translational research index transl
show all

Download the ESMO 2012 Abstract Book - Oxford Journals

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?